Celemics Extraordinary General Meeting Approves Article Changes and Appointment of Five New Directors, Business Purpose Expanded

Celemics disclosed on July 13, 2026 that its extraordinary general meeting approved all agenda items including partial amendments to the articles of incorporation and the appointment of five new directors consisting of two inside directors and two outside directors.
The amended articles expand the company's business purposes to include medical institution management support and consulting, defense and bio offset trade related businesses, and the establishment and operation of investment associations and funds.
Shareholder attendance was low at 42.9% of total voting shares, but among attending shareholders the approval rate reached 99.9% ensuring smooth passage of all resolutions.
Newly appointed inside directors are G&M director Youn Gyo-jung, Seoul National University researcher Kim Jun-hyung, and Haengbokmom Culture and Arts Cooperative chairperson Chae Young-ran. Outside directors are Sungkyunkwan University emeritus professor Im Geon-myeon and Medigard research center head Choi Seok-mun.
The EGM did not include any agenda items related to capital changes or shareholder return policies, limiting its direct short-term impact on the stock price.
[AI Summary]Celemics expanded its business scope into investment funds and defense sectors through article amendments, but no concrete funding or execution plans were disclosed, limiting near-term earnings expectations. While the new board members bring expertise, the stock as a high-growth name remains subject to volatility.